Evidence map›Paper›PMID 28349353›Full record

ReviewDrugs2017

Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases.

Mario Cazzola, Luigino Calzetta, Barbara Rinaldi, Clive Page, Giuseppe Rosano, Paola Rogliani, Maria Gabriella Matera

Abstract readReview
PubMed Publisher
In one paragraph

Review in Drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Emerging Anti-Inflammatory COPD Treatments: Potential Cardiovascular Impacts.International journal of chronic obstructive pulmonary disease · 2024
    Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Cardiovascular disease and COPD: dangerous liaisons?European respiratory review : an official journal of the European Respiratory Society · 2018
    Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Mario CazzolaDepartment of Systems Medicine, University of Rome Tor Vergata, Rome, Italy. mario.cazzola@uniroma2.it.
Luigino CalzettaDepartment of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Barbara RinaldiDepartment of Experimental Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
Clive PageSackler Institute of Pulmonary Pharmacology, King's College London, London, UK.
Giuseppe RosanoCardiovascular and Cell Science Institute, St George's Hospital NHS Trust, University of London, London, UK.
Paola RoglianiDepartment of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Maria Gabriella MateraDepartment of Experimental Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
University of Rome Tor Vergata · ITUniversity of Campania "Luigi Vanvitelli" · ITIstituto di Ricovero e Cura a Carattere Scientifico San RaffaeleKing's College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) and cardiovascular diseases often coexist. The mechanistic links between these two diseases are complex, multifactorial and not entirely understood, but they can influence the therapeutic approach. Therapy can be primarily directed towards treating the respiratory symptoms and reducing lung inflammation. Smoking cessation, bronchodilators and inhaled corticosteroids are central to this therapeutic approach. The underlying pathophysiological mechanisms that are responsible for the increased cardiovascular risk in COPD remain unclear, but might include arterial stiffness, inflammation and endothelial dysfunction as a consequence of systemic exposure to chemicals in cigarette smoke or airborne pollution. Therefore, it is plausible that treatment of cardiovascular co-morbidities might reduce morbidity and mortality in patients with COPD and, consequently, therapy of COPD should be shifted to the treatment of cardiovascular diseases and systemic inflammation. In support of this approach, early data suggest that patients with COPD treated with angiotensin-converting enzyme inhibitors, angiotensin II type 1 receptor blockers, statins, anti-platelet drugs or β-adrenoceptor blockers may have improved survival and reduced hospitalisation from acute exacerbations of COPD. In this review, the potential impact of traditional therapies for COPD that are centred on treating the lungs and newer strategies potentially able to affect and mitigate cardiovascular risks in patients with COPD are discussed.

Indexed as

Adrenal Cortex HormonesBronchodilator AgentsCardiovascular DiseasesComorbidityDisease ManagementHumansInflammationPulmonary Disease, Chronic ObstructiveSmoking CessationAdrenal Cortex HormonesBronchodilator Agents

Identifiers

PMID28349353
OpenAlexW2603592791

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.